Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

NCT04683250 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

244

Enrollment

INDUSTRY

Sponsor class

Conditions

RET-altered Non Small Cell Lung Cancer
RET-altered Solid Tumors

Interventions

DRUG: TAS0953/HM06
DRUG: TAS0953/HM06

Sponsor

Taiho Pharmaceutical Co., Ltd.

Collaborators

[object Object]